1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue
1.4 Market by Type
1.4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Vitamin E & Pioglitazone
1.4.3 Obeticholic Acid (OCA)
1.4.4 Elafibranor
1.4.5 Selonsertib & Cenicriviroc
1.5 Market by Application
1.5.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application: 2020 VS 2026
1.5.2 Hospital Pharmacy
1.5.3 Online Provider
1.5.4 Retail Pharmacy
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Perspective (2015-2026)
2.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Growth Trends by Regions
2.2.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Growth Strategy
2.3.6 Primary Interviews with Key Non-Alcoholic Steatohepatitis (NASH) Drugs Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Market Size
3.1.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Revenue (2015-2020)
3.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Players (2015-2020)
3.1.3 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Ratio
3.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in 2019
3.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Key Players Head office and Area Served
3.4 Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Product Solution and Service
3.5 Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Type (2015-2020)
4.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)
5.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2020)
6.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Key Players in North America (2019-2020)
6.3 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020)
6.4 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)
7 Europe
7.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2020)
7.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Key Players in Europe (2019-2020)
7.3 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020)
7.4 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)
8 China
8.1 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2020)
8.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Key Players in China (2019-2020)
8.3 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020)
8.4 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)
9 Japan
9.1 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2020)
9.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Key Players in Japan (2019-2020)
9.3 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020)
9.4 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2020)
10.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)
11 India
11.1 India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2020)
11.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Key Players in India (2019-2020)
11.3 India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020)
11.4 India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2020)
12.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020)
12.4 Central & South America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 AstraZeneca
13.1.1 AstraZeneca Company Details
13.1.2 AstraZeneca Business Overview
13.1.3 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
13.1.4 AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020))
13.1.5 AstraZeneca Recent Development
13.2 Conatus Pharmaceuticals
13.2.1 Conatus Pharmaceuticals Company Details
13.2.2 Conatus Pharmaceuticals Business Overview
13.2.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
13.2.4 Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
13.2.5 Conatus Pharmaceuticals Recent Development
13.3 Enzo Biochem
13.3.1 Enzo Biochem Company Details
13.3.2 Enzo Biochem Business Overview
13.3.3 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
13.3.4 Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
13.3.5 Enzo Biochem Recent Development
13.4 Galmed Pharmaceuticals
13.4.1 Galmed Pharmaceuticals Company Details
13.4.2 Galmed Pharmaceuticals Business Overview
13.4.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
13.4.4 Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
13.4.5 Galmed Pharmaceuticals Recent Development
13.5 Genfit
13.5.1 Genfit Company Details
13.5.2 Genfit Business Overview
13.5.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
13.5.4 Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
13.5.5 Genfit Recent Development
13.6 Gilead
13.6.1 Gilead Company Details
13.6.2 Gilead Business Overview
13.6.3 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
13.6.4 Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
13.6.5 Gilead Recent Development
13.7 Horizon Pharma
13.7.1 Horizon Pharma Company Details
13.7.2 Horizon Pharma Business Overview
13.7.3 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
13.7.4 Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
13.7.5 Horizon Pharma Recent Development
13.8 Immuron
13.8.1 Immuron Company Details
13.8.2 Immuron Business Overview
13.8.3 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
13.8.4 Immuron Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
13.8.5 Immuron Recent Development
13.9 Intercept Pharmaceuticals
13.9.1 Intercept Pharmaceuticals Company Details
13.9.2 Intercept Pharmaceuticals Business Overview
13.9.3 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
13.9.4 Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
13.9.5 Intercept Pharmaceuticals Recent Development
13.10 Novo Nordisk
13.10.1 Novo Nordisk Company Details
13.10.2 Novo Nordisk Business Overview
13.10.3 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
13.10.4 Novo Nordisk Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
13.10.5 Novo Nordisk Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Non-Alcoholic Steatohepatitis (NASH) Drugs Key Market Segments
Table 2. Key Players Covered: Ranking by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue
Table 3. Ranking of Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Vitamin E & Pioglitazone
Table 6. Key Players of Obeticholic Acid (OCA)
Table 7. Key Players of Elafibranor
Table 8. Key Players of Selonsertib & Cenicriviroc
Table 9. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 10. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 11. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 12. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Regions (2015-2020)
Table 13. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 14. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Regions (2021-2026)
Table 15. Market Top Trends
Table 16. Key Drivers: Impact Analysis
Table 17. Key Challenges
Table 18. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Growth Strategy
Table 19. Main Points Interviewed from Key Non-Alcoholic Steatohepatitis (NASH) Drugs Players
Table 20. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Players (2015-2020) (Million US$)
Table 21. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Players (2015-2020)
Table 22. Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs as of 2019)
Table 23. Global Non-Alcoholic Steatohepatitis (NASH) Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Product Solution and Service
Table 26. Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Drugs Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) (Million US$)
Table 29. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Share by Type (2015-2020)
Table 30. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Type (2021-2026)
Table 31. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Share by Application (2015-2020)
Table 32. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) (Million US$)
Table 33. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Share by Application (2021-2026)
Table 34. North America Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (2019-2020) (Million US$)
Table 35. North America Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share (2019-2020)
Table 36. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) (Million US$)
Table 37. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2015-2020)
Table 38. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) (Million US$)
Table 39. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2015-2020)
Table 40. Europe Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (2019-2020) (Million US$)
Table 41. Europe Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share (2019-2020)
Table 42. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) (Million US$)
Table 43. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2015-2020)
Table 44. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) (Million US$)
Table 45. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2015-2020)
Table 46. China Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (2019-2020) (Million US$)
Table 47. China Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share (2019-2020)
Table 48. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) (Million US$)
Table 49. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2015-2020)
Table 50. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) (Million US$)
Table 51. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2015-2020)
Table 52. Japan Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (2019-2020) (Million US$)
Table 53. Japan Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share (2019-2020)
Table 54. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) (Million US$)
Table 55. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2015-2020)
Table 56. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) (Million US$)
Table 57. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2015-2020)
Table 58. Southeast Asia Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (2019-2020) (Million US$)
Table 59. Southeast Asia Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share (2019-2020)
Table 60. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) (Million US$)
Table 61. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2015-2020)
Table 62. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) (Million US$)
Table 63. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2015-2020)
Table 64. India Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (2019-2020) (Million US$)
Table 65. India Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share (2019-2020)
Table 66. India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) (Million US$)
Table 67. India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2015-2020)
Table 68. India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) (Million US$)
Table 69. India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2015-2020)
Table 70. Central & South America Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (2019-2020) (Million US$)
Table 71. Central & South America Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share (2019-2020)
Table 72. Central & South America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) (Million US$)
Table 73. Central & South America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2015-2020)
Table 74. Central & South America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) (Million US$)
Table 75. Central & South America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2015-2020)
Table 76. AstraZeneca Company Details
Table 77. AstraZeneca Business Overview
Table 78. AstraZeneca Product
Table 79. AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (Million US$)
Table 80. AstraZeneca Recent Development
Table 81. Conatus Pharmaceuticals Company Details
Table 82. Conatus Pharmaceuticals Business Overview
Table 83. Conatus Pharmaceuticals Product
Table 84. Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (Million US$)
Table 85. Conatus Pharmaceuticals Recent Development
Table 86. Enzo Biochem Company Details
Table 87. Enzo Biochem Business Overview
Table 88. Enzo Biochem Product
Table 89. Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (Million US$)
Table 90. Enzo Biochem Recent Development
Table 91. Galmed Pharmaceuticals Company Details
Table 92. Galmed Pharmaceuticals Business Overview
Table 93. Galmed Pharmaceuticals Product
Table 94. Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (Million US$)
Table 95. Galmed Pharmaceuticals Recent Development
Table 96. Genfit Company Details
Table 97. Genfit Business Overview
Table 98. Genfit Product
Table 99. Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (Million US$)
Table 100. Genfit Recent Development
Table 101. Gilead Company Details
Table 102. Gilead Business Overview
Table 103. Gilead Product
Table 104. Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (Million US$)
Table 105. Gilead Recent Development
Table 106. Horizon Pharma Company Details
Table 107. Horizon Pharma Business Overview
Table 108. Horizon Pharma Product
Table 109. Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (Million US$)
Table 110. Horizon Pharma Recent Development
Table 111. Immuron Business Overview
Table 112. Immuron Product
Table 113. Immuron Company Details
Table 114. Immuron Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (Million US$)
Table 115. Immuron Recent Development
Table 116. Intercept Pharmaceuticals Company Details
Table 117. Intercept Pharmaceuticals Business Overview
Table 118. Intercept Pharmaceuticals Product
Table 119. Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (Million US$)
Table 120. Intercept Pharmaceuticals Recent Development
Table 121. Novo Nordisk Company Details
Table 122. Novo Nordisk Business Overview
Table 123. Novo Nordisk Product
Table 124. Novo Nordisk Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (Million US$)
Table 125. Novo Nordisk Recent Development
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type: 2020 VS 2026
Figure 2. Vitamin E & Pioglitazone Features
Figure 3. Obeticholic Acid (OCA) Features
Figure 4. Elafibranor Features
Figure 5. Selonsertib & Cenicriviroc Features
Figure 6. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application: 2020 VS 2026
Figure 7. Hospital Pharmacy Case Studies
Figure 8. Online Provider Case Studies
Figure 9. Retail Pharmacy Case Studies
Figure 10. Non-Alcoholic Steatohepatitis (NASH) Drugs Report Years Considered
Figure 11. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Regions: 2020 VS 2026
Figure 13. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Players in 2019
Figure 16. Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in 2019
Figure 18. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Bottom-up and Top-down Approaches for This Report
Figure 26. Data Triangulation
Figure 27. Key Executives Interviewed
【掲載企業】
AstraZeneca、Conatus Pharmaceuticals、Enzo Biochem、Galmed Pharmaceuticals、Genfit、Gilead、Horizon Pharma、Immuron、Intercept Pharmaceuticals、Novo Nordisk